RA0816

antibody from Oursmab

Targeting: VSIR B7-H5, B7H5, C10orf54, Dies1, GI24, PD-1H, SISP1, VISTA

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0816

Provider

Oursmab

Product name

Onvatilimab (Biosimilar Reference Antibody) (VSIR)

Antibody type

Monoclonal

Description

Onvatilimab (also known as JNJ-61610588 or CI-8993) is a humanized IgG1-kappa monoclonal antibody that targets V-domain Ig suppressor of T-cell activation (VISTA), an inhibitory immune checkpoint protein. As an IgG1 isotype, it is designed to potentially engage immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC). By binding to VISTA, onvatilimab blocks its interaction with ligands (e.g., VSIG3, PSGL-1), thereby reversing VISTA-mediated suppression of T-cell activation and cytokine production. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors, with the aim of restoring anti-tumor immunity, particularly in combination with other immunotherapies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.